Reported Tigecycline Overdose Fatalities
No tigecycline overdose fatalities have been reported in clinical trials, post-marketing surveillance, or FDA adverse event databases as of the latest available data. The drug's prescribing information notes that overdose experience is limited, with cases managed supportively (e.g., hemodialysis removes minimal amounts), but no deaths are documented [1][2].
What Happens in Tigecycline Overdose?
Overdoses typically cause nausea, vomiting, and elevated liver enzymes, mirroring common side effects at therapeutic doses. In animal studies, high doses led to reversible liver changes, but human cases show no progression to fatal outcomes. Supportive care like gastric lavage or activated charcoal is recommended, though efficacy is unproven [1][3].
Key Adverse Events and Mortality Risks
Tigecycline carries a black box warning for increased mortality risk (4% vs. 3% in comparators) in ventilator-associated pneumonia and complicated intra-abdominal infections, driven by all-cause mortality, not overdose. Sepsis and superinfections contribute most to deaths, not toxicity from excess dosing [1][2].
Clinical Trial and Post-Marketing Data
Phase 3 trials (over 5,000 patients) reported no overdose deaths. FDA's FAERS database (through 2023) lists tigecycline overdoses but zero fatalities; most resolve without sequelae. European Medicines Agency summaries align, citing no overdose-related mortality [2][4].
Comparison to Similar Antibiotics
Unlike glycopeptides (e.g., vancomycin overdoses with rare nephrotoxic fatalities), tigecycline's wide therapeutic index and low dialyzability reduce overdose lethality. Tetracycline overdoses historically caused fanconi syndrome but seldom death [3].
[1] Tygacil (tigecycline) Prescribing Information, FDA, 2010 (updated)
[2] FDA Tygacil Safety Review
[3] Tigecycline, StatPearls, NCBI, 2023
[4] Tygacil EMA Assessment Report